deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00253630

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma

Sponsor: National Cancer Institute (NCI)

Conditions Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Nodal Marginal Zone Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma
Interventions Laboratory Biomarker Analysis Vorinostat
Updated 8 times since 2017 Last updated: Feb 5, 2018 Started: Sep 30, 2005 Primary completion: May 31, 2016 Completion: May 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue and Nodal Marginal Zone Lymphoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 8 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshotCompleted~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Mar 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations